Our History

Orphazyme was founded in Denmark in 2009 based on a scientific discovery about the role of heat shock proteins, which was described in a well-cited article published in the journal Nature. One of the lead authors of that paper, Thomas Kirkegaard Jensen, is a founder of our company and our Chief Scientific Officer.

Today, we have translated that scientific discovery into a late-stage clinical development program. We are working to obtain regulatory approvals that will allow us to bring a new kind of treatment to patients, applying our specialized expertise in heat shock proteins for the benefit of people living with neurodegenerative orphan diseases.

#WhyWeShowUp

CARE for people with rare diseases with a high unmet medical need.
WORK tirelessly to conduct the most thorough, diligent research and bring results to patients as quickly and safely as possible.
BUILD powerful relationships with everyone connected to the diseases we are treating, to learn from the wider community.

COURAGE

PERSEVERANCE

CARE

INTEGRITY

US MANAGEMENT TEAM

Orphazyme’s growing US team includes industry experts with experience implementing several successful product launches in rare and ultra-rare diseases. We are dedicated to developing and delivering effective treatments for people living with rare diseases, and passionate about engaging and collaborating with the communities we serve.

Molly Painter

Molly Painter

Orphazyme US President

  • MBA, Northwestern University
  • More than 20 years of healthcare experience
  • Direct accountability for six biotech launches, with involvement in more than ten
Terri Stevens

Terri Stevens

Chief Business Officer

  • BS Animal Science, MS Biochemistry, Juris Doctor (Law)
  • 35 years (Research Pharmacologist, IP Lawyer, Corporate Lawyer, General Counsel, BD&L, M&A as Chief Corporate Development Officer and CBO)
  • Been on executive Management teams of a company that launched rare disease products (2 products in Cystic Fibrosis)
Daniel Gallo

Daniel Gallo

Medical Affairs

  • PhD, Northwestern University
  • More than nine years of healthcare experience
  • Supported seven rare or orphan disease treatments, and participated in the launch of three
Tim Kanter

Tim Kanter

Market Access, Trade
& Pricing

  • MBA, University of South Florida and BS, University of Florida
  • More than 20 years of healthcare experience
  • Supported launches of more than 10 treatments
Patrick Lennon

Patrick Lennon

Analytics & Insights

  • MBA, Katz Graduate School of Business at the University of Pittsburgh
  • More than 14 years of healthcare experience
  • Five rare or orphan disease treatments supported or launched
Kevin McCann

Kevin McCann

Finance

  • BS in Accounting, University of Iowa
  • More than 20 years of healthcare experience
  • Supported more than five rare or orphan disease treatments
Abhijit Pangu

Abhijit Pangu

Regulatory Affairs

  • Master of Sciences of Pharmacy, Goa University
  • Nearly 20 years of healthcare experience
Molly Poarch

Molly Poarch

Corporate Communications

  • Bachelor’s in Communications
  • 17 yrs in healthcare & health communications
  • 3 rare disease product launches
Sulin Shah

Sulin Shah

US General Counsel

  • JD, Northwestern University School of Law
  • More than 15 years of healthcare experience
  • Supported 11 rare disease products, including three new launch products
Regan Sherman

Regan Sherman

Patient Advocacy

  • BA, James Madison University
  • More than 15 years of healthcare experience
  • Supported seven rare or orphan disease treatments
Izabella Tyszler

Izabella Tyszler

Marketing & Field Execution

  • BS, DePaul University
  • More than 15 years of healthcare experience
  • Led and managed more than 7 rare & orphan disease launches